Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study

Recruiting now · Phase 2

Conditions studied: Neoplasm Malignant, Colon Cancer Stage 4

In brief

This prospective Phase II study aims to evaluate the efficacy and safety of a modified FOLFOXIRI regimen in the treatment of metastatic colorectal cancer (MCRC). FOLFOXIRI, though effective, is known for its high toxicity, necessitating close monitoring and dose adjustments. . The primary endpoint is to assess the impact on the objective response rate and evaluate both acute and delayed toxicity. The secondary endpoints include studying the treatment's effectiveness as conversion therapy, along with disease-free survival (DFS) and overall survival (OS). The tertiary endpoint focuses on evaluating predictive and prognostic factors of significance. This study seeks to balance the efficacy of FOLFOXIRI with a modified dose to minimize toxicity while maintaining therapeutic benefits, providing a potentially safer and effective option for patients with MCRC.

Key facts

Study ID

NCT06575127

Run by

Al-Azhar University

People needed

60

Starts

2024-08-17

Expected to finish

2026-09-01

Last updated by the study team

2024-08-28

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed unrespectable or metastatic colorectal cancer with or without primary tumor in situ.
• Patients were required to have measurable disease according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumors) (Eisenhauer EA,2009)
• ECOG PS 0-1 better to exclude PS II as this protocol is known to be toxic
• Adequate baseline hematology and clinical chemistry labs
• Adequate cardiac function

You may not qualify if…

• Double Malignancy
• DPYD mutant patients
• Peripheral neuropathy grade 3 or higher patient due to other comorbidities
• Inflammatory bowel syndrome or any other chronic GIT disease
• Prior exposure to chemotherapy treatment for colorectal cancer in the metastatic setting
• Patients who have contraindications for one or more of the study protocol drugs

Where it is running

• Al Hussien University Hospital — Cairo, Cairo Governorate, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.